Update in growth hormone insensitivity syndrome

Current Opinion in Endocrinology and Diabetes

Volumn 9, Issue 1, 2002, Pages 21-25

  Savage, Martin O ^a   Blair, Joanne C ^a   Clark, Adrian J L ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

CHILD; FEMALE; GENE MUTATION; GENETIC DISORDER; GENETIC HETEROGENEITY; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE INSENSITIVITY SYNDROME; HORMONE RESISTANCE; HUMAN; HYPOGLYCEMIA; LARON SYNDROME; MAJOR CLINICAL STUDY; MALE; RECEPTOR GENE; REVIEW; SHORT STATURE;

EID: 0036301727     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200202000-00004     Document Type: Review

References (57)

1. Genetic pituitary dwarfism with high serum concentration of growth hormone: A new inborn error of metabolism?
2. Growth hormone insensitivity: A proposed revised classification
3. Laron syndrome: Typical and atypical forms
4. Defect of growth hormone receptors in the liver of two patients with Laron-type dwarfism
5. Growth hormone (GH) insensitivity due to primary GH receptor deficiency
6. Growth hormone receptor and serum binding protein: Purification, cloning and expression
7. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism
8. Laron dwarfism and mutations of the growth hormone receptor gene
9. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations
10. Laron syndrome primary growth hormone resistance
11. Lessons from the genetics of Laron syndrome
12. The insulin-like growth factor binding proteins and insulin-like growth factor bio-activity in Laron-type dwarfism
13. Growth hormone receptor deficiency in Ecuador: Clinical and biochemical phenotype in two populations
14. IGF-I treatment of growth hormone insensitivity
15. Phenotype: Genotype relationships in growth hormone insensitivity syndrome
16. Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity syndrome
17. Congenital idiopathic growth hormone deficiency associated with prenatal and early postnatal growth failure
18. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome)
19. Mutations of the growth hormone receptor in children with idiopathic short stature
20. Partial growth hormone insensitivity: The role of growth hormone receptor mutations in idiopathic short stature
21. Partial growth hormone insensitivity
22. A dominant-negative mutation of the growth hormone receptor causes familial short stature
23. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain
24. Partial growth hormone insensitivity
25. Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature
26. Growth hormone receptor mutations in children with idiopathic short stature
27. Heterozygous mutation in the WSXWS equivalent motif of the growth hormone receptor in a child with poor response to growth hormone therapy
28. Study of GH sensitivity in Chilean patients with idiopathic short stature
29. Functional characterization of truncated growth (GH) receptor - (1-277) Causing partial GH insensitivity syndrome with high GH-binding protein
30. Stature in Ecuadorians heterozygous for growth hormone receptor gene E180 splice mutation does not differ from that of homozygous normal relatives
31. Constancy of somatomedin response to growth hormone treatment of hypopituitary dwarfism, and lack of correlation with growth rate
32. Short-term increments of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 predict the growth response to growth hormone (GH) therapy in GH-sensitive children
33. The little women of Loja: Growth hormone receptor deficiency in an inbred population of southern Ecuador
34. Insulin-like growth factor binding protein-3 generation: An index of growth hormone insensitivity
35. Changes in serum IGF-I and IGFBP-3 concentrations during the IGF-I generation test performed prospectively in children with short stature
36. Abnormal GH receptor signalling in children with idiopathic short stature
37. Modification of growth hormone dose and frequency of sampling for IGF-I and IGFBP-3 in the IGF-I generation test in children with idiopathic short stature
38. The insulin-like growth factor-I (IGF-I) generation test: A marker of growth hormone (GH) sensitivity in GH deficiency, GH insensitivity, and idiopathic short stature
39. Growth hormone insensitivity; from Laron Syndrome to idiopathic short stature
40. Growth responses to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities
41. Novel compound heterozygous mutations of growth hormone (GH) receptor gene in a patient with GH insensitivity syndrome
42. Nine novel growth hormone receptor gene mutations in patients with Laron Syndrome
43. Growth hormone insensitivity: Physiologic and genetic basis, phenotype and treatment
44. IGF-deficiency
45. A homozygous splice site mutation affecting the intracellular domain of the growth hormone receptor resulting in Laron syndrome with elevated growth hormone binding protein
46. A homozygous splicing mutation, which results in a growth hormone receptor lacking transmembrane and intracellular domains, gives rise to Laron syndrome with elevated GH-binding protein
47. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron Syndrome) with positive GH-binding activity by abolishing receptor homodimerization
48. Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity
49. Is there a medical need to explore the clinical use of insulin-like growth factor-I?
50. Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I)
51. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency
52. The effect of recombinant human insulin-like growth factor-i treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome)
53. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein 3 reduces insulin requirements in insulin-dependent type I diabetes: Evidence for in vivo biologic activity
54. Treatment of growth hormone insensitivity syndrome with insulin-like growth factor-I: Long-term results of the European Multicenter study
55. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: A clinical research center study
56. Recombinant human insulin-like growth factor-I has significant anabolic effects in adults with growth hormone receptor deficiency: Studies of protein, glucose and lipid metabolism
57. Uses of human insulin-like growth factor-I in clinical conditions